<DOC>
	<DOCNO>NCT02557295</DOCNO>
	<brief_summary>An Observational , Prospective Cohort Study Evaluate Safety Efficacy RemsimaTM Patients Rheumatoid Arthritis .</brief_summary>
	<brief_title>An Observational Study Evaluate Safety Efficacy Remsima™ Patients With RA</brief_title>
	<detailed_description>The primary objective study ass long-term safety Remsima™ Rheumatoid Arthritis ( RA ) patient evaluation event special interest ( ESI ) 5 year exploratory compare patient receive Remsima™ patient receive non-biologic treatment anti-TNF drug . In order ass primary study outcome , follow ESI evaluate : - Hepatitis B virus reactivation - Congestive heart failure - Opportunistic infection ( exclude tuberculosis ) - Serious infection include sepsis ( exclude opportunistic infection tuberculosis ) - Tuberculosis ( TB ) - Serum sickness ( delay hypersensitivity reaction ) - Haematologic reaction - Systemic lupus erythematosus/lupus like syndrome - Demyelinating disorder - Lymphoma ( HSTCL ) - Hepatobiliary event - Hepatosplenic T cell lymphoma ( HSTCL ) - Serious infusion reaction re-induction regimen follow disease flare - Sarcoidosis/sarcoid-like reaction - Leukaemia - Malignancy ( exclude lymphoma ) - Skin cancer - Pregnancy exposure† - Infusion reaction associate shortened infusion duration - Others The secondary objective study evaluate efficacy . Further , additional safety Remsima™ RA patient , comparison patient receive non-biologic treatment anti-TNF drug . Health-economics parameter also assess .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>1 . Adult patient 2 . Patients active RA 3 . Patients ( legal guardian , applicable ) willing give inform consent long term followup include access medical record 1 . Patients history hypersensitivity infliximab 2 . Patients current past history chronic infection 3 . Patients moderate severe heart failure ( NYHA class III/IV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>